ThinkEquity Initiates Coverage on Allos Therapeutics (ALTH) with a Buy
More News related to ALTH
- Allos Therapeutics to Present at BIO CEO & Investor Conference
- BioCentury Publishes BioTech Picks for FY10 (HGSI, VRTX, AMGN, More...)
- BioCentury Publishes Investor Picks for New Biotech Bellwethers in 2010
- Notable Analyst Rating Changes 1/8: HAL, AMAT, JCP, AGU, ESV, RDN, More Upgraded; M, KO, STX, ERIC, WEN, PCS, More Downgraded
- J.P. Morgan Intiates Coverage on Allos Therapeutics (ALTH) with a Buy
More News related to New Coverage
- Janney Montgomery Scott Initiates Coverage on Papa John's International (PZZA) with a Neutral
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
- Oscar Gruss Initiates Coverage Airgas (ARG) with a Buy
- Sidoti & Co Initiates Coverage on Solutia (SOA) with a Buy
- RBC Capital Initiates Coverage on Questar (STR) with a Sector Perform
ThinkEquity initiates coverage on Allos Therapeutics (Nasdaq: ALTH) with a Buy rating.
To see all the upgrades/downgrades on shares of ALTH, visit our Analyst Ratings page.
Allos Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing small molecule drugs for the treatment of cancer.
Related Categories
New CoverageStocks Mentioned
+0.07Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
